ClinicalTrials.gg
RecruitingNCT07517198Updated Jun 10, 2026

Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors

A Phase 1 interventional study of EXS74539 in Solid Tumor, Small Cell Lung Cancer (SCLC) and High Grade Neuroendocrine Cancer, sponsored by Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.. Recruiting at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-10.

Sponsored by Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 630 studies in Small Cell Lung Carcinoma with a site in United States — 111 open to participants now, 182 under way, 26 of them phase 3. Small Cell Lung Carcinoma · United States.

Planned enrollment
316th of 551
40 · median 55
Started
2026
with 37 others
Phase 1
183 of 630
24 open now
Primary completion
2029-03
later than 139 of 181 live
Registered
615th of 630
by date

Among the 630 studies in Small Cell Lung Carcinoma with a site in United States, this one is the 316th largest by planned enrollment of the 551 interventional ones that give a count, is one of 38 that started in 2026, is one of 183 in phase 1, reaches primary completion later than 139 of the 181 other live ones, and was the 615th registered.

Small Cell Lung Carcinoma

1,302 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

111 of the 630 studies in Small Cell Lung Carcinoma with a site in United States are open now. Recruiting first, the newest first:

106 more — sign in →

All 111 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 630 studies in Small Cell Lung Carcinoma with a site in United States, or all of them as a file.
02

Study summary

The primary purpose of this study is to determine the safety, tolerability, and maximum tolerated dose (MTD) of EXS74539 (REC-4539) in participants with select solid tumors.

03

Conditions studied

  • Solid Tumor
  • Small Cell Lung Cancer (SCLC)
  • High Grade Neuroendocrine Cancer
  • Small Cell Carcinomas of Non-lung Origin
  • Non-small Cell Lung Cancer (NSCLC)
  • Prostate Cancer
  • Ovarian Cancer
  • Renal Carcinoma (Clear and Non-clear Cell)
  • Head and Neck Squamous Cell Carcinoma (HNSCC)
  • Hepatic Cancer
  • Gastric Cancer
  • Triple-negative Breast Cancer (TNBC)

Keywords

  • Solid Tumors
  • Small Cell Lung Cancer (SCLC)
  • High grade neuroendocrine cancer
  • Small cell carcinomas of non-lung origin
  • Non-small cell lung cancer (NSCLC)
  • Prostate cancer
  • Ovarian cancer
  • Renal carcinoma (clear and non-clear cell)
  • Head and neck squamous cell carcinoma (HNSCC)
  • Hepatic cancer
  • Gastric cancer
  • Triple-negative breast cancer (TNBC)
  • LSD1 inhibitor
  • EXS74539
  • REC-4539
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • (ECOG) performance status of 0-1.
  • confirmed diagnosis of the following solid tumors:

    • SCLC
    • High grade neuroendocrine or small cell carcinomas of non-lung origin
    • Non-small cell lung cancer [NSCLC]
    • Prostate cancer
    • Ovarian cancer
    • Renal carcinoma [clear and non-clear cell]
    • Head and neck squamous cell carcinoma
    • Hepatic cancer
    • Gastric cancer
    • Triple-negative breast cancer [TNBC]
  • Participant disease should have progressed, or the participants should have been intolerant to at least one prior standard systemic therapy for their respective underlying .
  • per (RECIST) version 1.1.

Key Exclusion Criteria:

  • Any medical or psychiatric condition that, in the opinion of the Investigator, could jeopardize or would compromise the participant's safety or ability to participate in the study.
  • Symptomatic , , or spinal cord compression due to disease. Participants with brain metastases must be clinically stable and off and anticonvulsants for ≥1 month prior to study treatment and not require any specific intervention for brain metastases.
  • Active and infection requiring systemic antibacterial, antiviral, or antifungal therapy \<7 days of the first scheduled dose of the study treatment.
  • Significant cardiac abnormalities.
  • Major surgery within 28 days prior to the start of study treatment.

Note: Other protocol-defined inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    EXS74539

    EXS74539

    Drug: EXS74539

Interventions

  • DrugEXS74539

    Oral administration

    Also known as: REC-4539

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Time frame: Up to 3 years

  2. Number of Participants with Dose-limiting Toxicity (DLT)

    Time frame: Up to 28 days

  3. Number of Participants with Dose Interruptions and Dose Modifications

    Time frame: Up to 3 years

Secondary outcomes

  1. Maximum Concentration (Cmax) of EXS74539

    Time frame: Cycle 1 Day 25 and at end of treatment (up to approximately 3 years)

  2. Time to Cmax (tmax) of EXS74539

    Time frame: Cycle 1 Day 25 and at end of treatment (up to approximately 3 years)

  3. Area Under the Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC[0-last]) of EXS74539

    Time frame: Cycle 1 Day 1 through end of treatment (up to approximately 3 years)

  4. Objective Response Rate (ORR)

    Time frame: Up to 3 years

  5. Duration of Response (DoR)

    Time frame: Up to 3 years

  6. Progression-free Survival (PFS)

    Time frame: Up to 3 years

  7. Overall Survival (OS)

    Time frame: Up to 3 years

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Mar 2029, 35 months after the start.

Of 111 industry-sponsored phase 1 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 63. This study's planned 35 months is below that.

Counting every sponsor, half of 143 studies reached it within 46 months; a quarter within 29 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2026
First posted
Apr 8, 2026
StartActual
Apr 13, 2026
Primary completionEst.
Mar 2029
CompletionEst.
Mar 2029
Last update
Jun 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07517198
Lead sponsor
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Apr 8, 2026
Start date
Apr 13, 2026
Primary completion
Mar 2029 (estimated)
Completion
Mar 2029 (estimated)
Last update
Jun 10, 2026

Study contacts

Exscientia AI Ltd.
Contact
clinicaltrials@recursion.com
385-374-1724

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion